ASCO 2022 | Association of 80 gene signature reclassification with neoadjuvant treatment response in BC

Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, provides an overview of the Neoadjuvant Breast Registry Symphony Trial (NBRST; NCT01479101), an observational, prospective study investigating the reclassification of traditional hormonal breast cancer subtyping (HR, ER, HER2 status) with an 80-gene molecular subtyping signature, BluePrint, with neoadjuvant treatment response. 15% pf ER+, HER2- tumors as Basal-Type, which had a similar pathologic complete response (pCR) to TNBC/Basal tumors and a significantly higher pCR than ER+/Lumunal A and ER+/Luminal B tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.